Glyburide vs Glimepiride — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Sulfonylurea

Glyburide

First FDA approval: 1984-05-01

Sulfonylurea

Glimepiride

First FDA approval: 2005-10-06

Lowest NADACAcquisition cost floor across all NDCs

$0.058Per unit

$0.024Per unit

Average NADACAcross all dosage forms and strengths

$0.078Up to $0.248

$0.033Up to $0.043

Generic manufacturersActive ANDA holders — FDA Orange Book

725 total ANDAs filed

828 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$4.5MFull year

$62.0MFull year

Part D claims (CY24)Total fills, all strengths

291K103K beneficiaries

6.8M2.2M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$15Per claim, all NDCs

$9Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

219Substantial friction

3Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

3Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

NoneClear

Generic availableFDA Orange Book

Yes7 manufacturers

Yes8 manufacturers